Skip to content

Netzwerk zielt auf die Diagnose und Behandlung antibiotikaresistenter Infektionen

Es gibt überzeugende Beweise dafür, dass Bakterien, Parasiten, Viren und Pilze Resistenzen gegen Antibiotika entwickeln. Infolgedessen werden Infektionen bei Menschen, Tieren und Pflanzen immer schwieriger und in manchen Fällen sogar unmöglich zu behandeln. Die Arzneimittelresistenz gegen weit verbreitete bakterielle Infektionen wird zu einer der globalen Gesundheitsbedrohungen. Die letzte COVID-19-Pandemie und die Mobilisierung der wissenschaftlichen Gemeinschaft zur Entwicklung eines wirksamen Impfstoffs sind noch immer in aller Munde. Ende August 2024 warnte die Weltgesundheitsorganisation vor der raschen Ausbreitung eines neuen virulenten Stamms von Affenpocken in Afrika und erklärte dies zu einem internationalen Gesundheitsnotfall. Nach Angaben der UNO sterben jedes Jahr rund 700.000 Menschen an bakterieller Arzneimittelresistenz, und Schätzungen zufolge könnten bis 2050 300 Millionen Menschen vorzeitig sterben. Die Weltgesundheitsorganisation (WHO) und die Europäische Kommission haben die Antibiotikaresistenz als eine der drei größten Gesundheitsbedrohungen des 21. Jahrhunderts eingestuft. Keine Medikamente oder therapeutischen Ansätze… 

more »Netzwerk zielt auf die Diagnose und Behandlung antibiotikaresistenter Infektionen

FDA decision on GLP-1 sparks unprecedented drug shortage dispute

After initially declaring the shortage of Eli Lilly's diabetes and weight-loss drugs over, the FDA reversed course, reopening the door to GLP-1 compounders. Pharmacies in the U.S. that make their own drugs can continue to profit from the GLP-1 gold rush – at least for now. But the FDA could pull their products from the market again. It all depends on whether the agency keeps branded GLP-1 drugs on the shortage list or not. The regulator is currently reviewing a decision it made earlier this month to remove Eli Lilly's diabetes blockbuster Mounjaro and its popular obesity drug Zepbound – both GLP-1 drugs – from the national shortage list. The original decision meant that pharmacies that make their own drugs were no longer allowed to produce their versions of Lilly's drugs, which use the same active ingredient called tirzepatide and are themselves extremely popular due to lower prices and availability… 

more »FDA decision on GLP-1 sparks unprecedented drug shortage dispute

Aerobic exercise prevents brain fog caused by chemotherapy

Clinical trial reveals improved self-reported cognitive function in women with breast cancer who started an exercise program when initiating chemotherapy. Many women who receive chemotherapy experience a decreased ability to remember, concentrate, and/or think—commonly referred to as “chemo-brain” or “brain fog”—both short- and long-term. In a recent clinical trial of women initiating chemotherapy for breast cancer, those who simultaneously started an aerobic exercise program self-reported greater improvements in cognitive function and quality of life compared with those receiving standard care. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society. The study, called the Aerobic exercise and CogniTIVe functioning in women with breAsT cancEr (ACTIVATE) trial, included 57 Canadian women in Ottawa and Vancouver who were diagnosed with stage I–III breast cancer and beginning chemotherapy. All women participated in 12–24 weeks of aerobic… 

more »Aerobic exercise prevents brain fog caused by chemotherapy

Revolutionizing the treatment of eating disorders through psychedelic research

  • News

In an insightful interview with Genomic Press, released today, Dr. Stephanie Knatz Peck, Associate Clinical Professor of Psychiatry at the University of California, San Diego (UCSD), reveals her groundbreaking work in the treatment of eating disorders and psychedelic research. The interview, featured in the journal Psychedelics, offers an intimate look into Dr. Knatz Peck’s journey from personal struggle with an eating disorder to becoming a leading innovator in the field. Dr. Knatz Peck’s research uniquely bridges clinical practice with cutting-edge interventions, focusing on developing novel treatments for anorexia nervosa (AN). Her work culminated in the creation of Temperament-Based Treatment with Supports (TBT-S), a behavioral intervention that has garnered international recognition. “I hope to contribute to finding better treatments for people suffering from treatment-resistant mental health conditions, particularly eating disorders,”…

more »Revolutionizing Eating Disorder Treatment Through Psychedelic Research

Okomera receives €1.5M grant to develop a microfluidic and AI-powered CRISPR editing platform for target validation

Okomera announces a Bpifrance grant to develop and standardize a novel CRISPR screening assay to accelerate drug discovery in oncology with Marseille’s leading cancer research center, CRCM. Okomera is developing a desktop platform for automated organoid screening using droplet microfluidics and AI to accelerate drug discovery. Their patented technology, developed over 10 years of research at Institut Pasteur and Ecole Polytechnique, enables multiplexing, co-culture, and high-throughput screening of drug candidates on patient-derived organoids (PDOs) in miniaturized format. AstraZeneca assisted with the grant application.

Inside SKBS: From Sample to Diagnosis

  • News

Those admitted to the urban Klinikum Braunschweig ward hardly notice the Hidden Heroes: the employees of laboratory medicine. LabNews watched the following video from the clinic from beginning to end. Our assessment: Highly recommended. The video is also suitable for school lessons – it provides solid information for anyone considering career orientation. Enjoy!

Health Minister expects no GVK contribution increase in 2026

  • News

Despite the sharp increase in statutory health insurance contributions at the turn of the year, Health Minister Karl Lauterbach (SPD) assesses his government's actions as cost-reducing. "I am implementing structural reforms and will ensure that contributions no longer increase as a matter of course in the long term," Lauterbach told "Bild am Sonntag". Thus, he is "the most cost-effective health minister for the health insurance funds." The Health Minister also anticipates a halt [...] Health Minister expects no GVK contribution increase in 2026

Doctors called to actively participate in health system reforms

The new president of the World Medical Association, Dr. Ashok Philip, has called on doctors worldwide to participate more actively in the development of health policy and health system reforms. The goal is to ensure the best possible patient care and protect the professional autonomy of doctors[1]. In his inaugural address at the World Medical Association's General Assembly in Helsinki, Dr. Philip emphasized the need for the medical profession to actively contribute to the further development of healthcare. Even though participation in health policy is time-consuming, it protects patients in the long run[1]. Threat to medical autonomy Dr. Philip, a specialist in internal medicine from Malaysia, warned of increasing threats to the professional autonomy of doctors. These have been exacerbated by rising healthcare costs and increased life expectancy. He defined medical autonomy as "the freedom to make clinical decisions about the care of individual patients" and described it as the most endangered… 

more »Doctors called to actively participate in health system reforms

IVDR shakes up laboratory medicine

The introduction of the EU regulation on in vitro diagnostics (IVDR) presents laboratory medicine with significant challenges. Here is a background article on the most important aspects: The IVDR (Regulation (EU) 2017/746) came into force on May 26, 2022, replacing the previous IVD Directive 98/79/EC. The aim is to improve patient safety through stricter requirements for in vitro diagnostics (IVD)[1]. New classification and conformity assessment A key change is the introduction of a risk-based classification system with four risk classes (A-D). This means that significantly more products fall into higher risk classes, requiring conformity assessment by a notified body. It is estimated that the proportion of IVDs requiring the involvement of a notified body will increase from the current 10-20% to 80-90%[1]. Shortage of notified bodies A core problem is the acute shortage of notified bodies for the IVDR. Currently, there are only 8 notified bodies notified under the IVDR, compared to 18 under the old directive[1]. This is leading to bottlenecks and delays… 

more »IVDR rattles laboratory medicine

Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab biosimilar to Stelara®

Accord announces that the CHMP has issued a positive opinion for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, used for a range of immunological diseases. The approval of Imuldosa® expands Accord Healthcare's biosimilar portfolio and strengthens Accord's autoimmune franchise, building on existing leading brands. Imuldosa® will be the 5th [...] Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab biosimilar to Stelara®